NCT01864083View on ClinicalTrials.gov

FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

August 29, 2017

Study Completion Date

August 29, 2017

Conditions
Breast Cancer
Interventions
PROCEDURE

Positron Emission Tomography (PET)

DRUG

Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC)

PROCEDURE

Positron emission mammography (PEM) When available

PROCEDURE

MR

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

GE Healthcare
All Listed Sponsors
collaborator

GE Healthcare

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER